A randomized Phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma
Open Access
- 15 July 1997
- Vol. 80 (2) , 218-224
- https://doi.org/10.1002/(sici)1097-0142(19970715)80:2<218::aid-cncr8>3.0.co;2-p
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Aromatase inhibitors-where are we now?British Journal of Cancer, 1996
- Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancerCancer, 1995
- Current perspectives on aromatase inhibitors in breast cancer.Journal of Clinical Oncology, 1994
- Response to third-line endocrine treatment for advanced breast cancerEuropean Journal Of Cancer, 1993
- Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitorThe Journal of Steroid Biochemistry and Molecular Biology, 1990
- Confidence Intervals for a Binomial Parameter Based on Multistage TestsBiometrics, 1987
- Aromatase activity in primary and metastatic human breast cancerCancer, 1987
- Suppression of estrogens with Aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: A reviewBreast Cancer Research and Treatment, 1981
- Aminoglutethimide Inhibits Extraglandular Estrogen Production in Postmenopausal Women with Breast Carcinoma*Journal of Clinical Endocrinology & Metabolism, 1978
- Assessment of response to therapy in advanced breast cancerPublished by Elsevier ,1977